AC Immune (NASDAQ:ACIU) Posts Earnings Results, Beats Estimates By $0.01 EPS

AC Immune (NASDAQ:ACIU) issued its quarterly earnings results on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01, FiscalAI reports. AC Immune had a negative net margin of 1,977.71% and a negative return on equity of 103.15%. The company had revenue of $1.40 million during the quarter, compared to the consensus estimate of $0.33 million.

AC Immune Price Performance

Shares of NASDAQ:ACIU traded up $0.10 during trading on Thursday, hitting $3.03. 240,866 shares of the company were exchanged, compared to its average volume of 256,910. The firm’s 50 day moving average price is $2.93 and its 200-day moving average price is $3.09. AC Immune has a 12-month low of $1.51 and a 12-month high of $4.00. The stock has a market capitalization of $308.36 million, a P/E ratio of -3.61 and a beta of 1.63.

Institutional Investors Weigh In On AC Immune

Hedge funds and other institutional investors have recently bought and sold shares of the stock. EFG International AG acquired a new position in AC Immune in the fourth quarter valued at $41,000. Private Advisor Group LLC acquired a new stake in shares of AC Immune during the third quarter worth about $48,000. Sei Investments Co. acquired a new stake in shares of AC Immune during the second quarter worth about $51,000. Goldman Sachs Group Inc. lifted its holdings in shares of AC Immune by 46.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after purchasing an additional 5,920 shares during the last quarter. Finally, Susquehanna International Group LLP purchased a new stake in shares of AC Immune in the 3rd quarter valued at about $63,000. 51.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of AC Immune in a report on Monday, April 20th. Wall Street Zen raised AC Immune from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Jefferies Financial Group restated a “buy” rating and issued a $7.00 price target on shares of AC Immune in a research note on Friday, March 13th. Finally, BTIG Research reaffirmed a “buy” rating and set a $8.00 price target on shares of AC Immune in a report on Monday, March 16th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, AC Immune presently has an average rating of “Hold” and an average target price of $9.00.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.